- Home
- LVTX vs RVPH Comparison
LVTX vs RVPH Comparison
Compare LVTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- RVPH
- Stock Information
- Founded
- LVTX 2016
- RVPH 2006
- Country
- LVTX Netherlands
- RVPH United States
- Employees
- LVTX N/A
- RVPH N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- RVPH Health Care
- Exchange
- LVTX Nasdaq
- RVPH Nasdaq
- Market Cap
- LVTX 33.9M
- RVPH 26.6M
- IPO Year
- LVTX 2021
- RVPH N/A
- Fundamental
- Price
- LVTX $1.42
- RVPH $0.46
- Analyst Decision
- LVTX Hold
- RVPH Strong Buy
- Analyst Count
- LVTX 3
- RVPH 5
- Target Price
- LVTX $1.75
- RVPH $9.00
- AVG Volume (30 Days)
- LVTX 48.5K
- RVPH 3.2M
- Earning Date
- LVTX 08-19-2025
- RVPH 08-13-2025
- Dividend Yield
- LVTX N/A
- RVPH N/A
- EPS Growth
- LVTX N/A
- RVPH N/A
- EPS
- LVTX N/A
- RVPH N/A
- Revenue
- LVTX $4,990,000.00
- RVPH N/A
- Revenue This Year
- LVTX N/A
- RVPH N/A
- Revenue Next Year
- LVTX N/A
- RVPH N/A
- P/E Ratio
- LVTX N/A
- RVPH N/A
- Revenue Growth
- LVTX N/A
- RVPH N/A
- 52 Week Low
- LVTX $0.85
- RVPH $0.30
- 52 Week High
- LVTX $2.21
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- LVTX 52.65
- RVPH 46.82
- Support Level
- LVTX $1.33
- RVPH $0.44
- Resistance Level
- LVTX $1.67
- RVPH $0.53
- Average True Range (ATR)
- LVTX 0.13
- RVPH 0.04
- MACD
- LVTX 0.00
- RVPH 0.02
- Stochastic Oscillator
- LVTX 25.00
- RVPH 56.07
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.